Q32 Bio

QTTB · Nasdaq · United States

Share price · QTTB

$8.53-6.76 (-44.21%) 3M

close as of 2026-11-18 · 24h delayed · vol 262K (0.5x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when QTTB's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 13 Jul 2026+90.7%
  2. 27 May 2026+81.2%
  3. 26 May 2026+22.2%

    Nothing announced by QTTB that day or the session before.

  4. 20 Apr 2026+13.7%
  5. 30 Mar 2026-18.6%
  6. 19 Mar 2026+14.8%

    Nothing announced by QTTB that day or the session before.

  7. 11 Mar 2026+15.4%
  8. 10 Mar 2026+17.5%
  9. 1 Dec 2025+74.4%

Share of unusual movement by asset

For each asset, the share of QTTB's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Bempikibart
events and moves
1035%
Other company news (earnings, financing, releases naming no asset)—16%
Sessions with no dated event—49%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
IL-7 receptor alphaMonoclonal antibody
Atopic DermatitisAlopecia Areata

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 July 2026Topline resultBempikibartSIGNAL-AA Part B 36-week topline results
US · Q32 Bio · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$5.2M$290M$8.9M-$4.4M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$4.3M$106M$8.9M-$3.1M operating cash flowreport ↗
2026-Q1—$3.2M$51M$7.6M-$6.3M operating cash flowreport ↗
2025-Q3—$3.6M$49M$7.4M-$4.2M operating cash flowreport ↗
2025-Q2—$5.2M$55M$9.5M-$11M operating cash flowreport ↗
2025-Q1—$7.1M$65M$11M-$12M operating cash flowreport ↗
2024-Q3—$14M$89M+ $0 short-term inv.$18M-$20M operating cash flowreport ↗
2024-Q2—$13M$98M+ $10.0M short-term inv.$17M-$22M operating cash flowreport ↗
2024-Q1—$9.8M$116M+ $20M short-term inv.—-$15M operating cash flowreport ↗
2023-Q3$0$18M$29M+ $74M short-term inv.$33M-$25M operating cash flowreport ↗
2023-Q2$0.3M$23M$77M+ $50M short-term inv.$35M-$24M operating cash flowreport ↗
2023-Q1$0.8M$20M$39M+ $111M short-term inv.$29M-$26M operating cash flowreport ↗
2022-Q3$0.8M$26M$43M+ $158M short-term inv.$34M-$25M operating cash flowreport ↗
2022-Q2$0.8M$21M$176M+ $49M short-term inv.$29M-$31M operating cash flowreport ↗
2022-Q1$0.8M$24M$248M+ $8.0M short-term inv.—-$31M operating cash flowreport ↗
2021-Q3$1.7M$24M$96M+ $92M short-term inv.$31M-$25M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$19M$48M—-$34M operating cash flowreport ↗

Q32 Bio reported collaboration arrangement revenue of $53.7M for 2025 versus none in 2024; total revenue was not separately disclosed. R&D expense was $19.16M, down 60.2% YoY, and cash and cash equivalents were $48.3M as of December 31, 2025. Full-year net income was $29.82M, driven by non-cash collaboration revenue and the ADX-097 sale, compared with a net loss of $47.7M in 2024.

The company completed enrollment in Part B of the SIGNAL-AA Phase 2a trial of bempikibart in alopecia areata, increasing the trial to 33 patients, with 36-week topline data expected mid-2026 and an open-label extension from Part A ongoing. It also completed a $10.5M registered direct offering in February 2026, sold the Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics for $12M in upfront and near-term milestone payments, with up to $592M in potential milestones plus tiered royalties, and terminated all remaining obligations to Amgen. Management expects cash, RDO proceeds, and guaranteed ADX-097 milestones to fund operations into Q4 2027.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$48M$78M+ $0 short-term inv.$12M-$68M operating cash flowreport ↗
2023-FY$1.2M$62M$39M+ $0 short-term inv.$28M-$96M operating cash flowreport ↗
2022-FY$3.2M$98M$34M+ $141M short-term inv.$1.3M-$114M operating cash flowreport ↗
2021-FY$34M$93M$108M+ $47M short-term inv.$24M-$110M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 4 purchases ($30.0M), 11 sales ($505K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-06Kalowski Lee · CFO and PresidentOpen-market sale1,301$8.32$11KForm 4
2026-10-06Violette Shelia M. · Chief Scientific OfficerOpen-market sale917$8.32$8KForm 4
2026-10-06Morrison Jodie Pope · director, CEOOpen-market sale3,221$8.32$27KForm 4
2026-08-25Violette Shelia M. · Chief Scientific OfficerOpen-market sale2,798$16.56$46KForm 4
2026-08-25Kalowski Lee · CFO and PresidentOpen-market sale3,972$16.56$66KForm 4
2026-08-25Morrison Jodie Pope · director, CEOOpen-market sale9,845$16.56$163KForm 4
2026-07-16Kalowski Lee · CFO and PresidentAward / grant53,250——Form 4
2026-07-16Morrison Jodie Pope · director, CEOAward / grant132,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 53 reporting institutions held 9.4M shares ($59.3M, 31.5% of shares outstanding).

#InstitutionSharesValue
1ORBIMED ADVISORS LLC2,252,987$14.5M
2Atlas Venture Life Science Advisors, LLC2,092,106$13.4M
3Opaleye Management Inc.1,256,228$8.1M
4Carlyle Group Inc.1,102,741$7.1M
5ARCH Venture Management, LLC320,482$2.1M
6ACORN CAPITAL ADVISORS, LLC315,052$2.0M
7VANGUARD CAPITAL MANAGEMENT LLC306,401$2.0M
8MACKENZIE FINANCIAL CORP246,304$1.6M
9Sanofi244,083$1.6M
10RENAISSANCE TECHNOLOGIES LLC206,915$1.3M
11MONIMUS CAPITAL MANAGEMENT, LP134,310$862K
12GEODE CAPITAL MANAGEMENT, LLC118,152$759K
13Pfizer Inc101,618$737K
14BlackRock, Inc.86,147$553K
15JANE STREET GROUP, LLC65,599$421K